215
Participants
Start Date
June 26, 2019
Primary Completion Date
June 30, 2027
Study Completion Date
May 31, 2028
Rapcabtagene autoleucel single agent
Single infusion of rapcabtagene autoleucel
Ibrutinib
Tablets or capsules for oral daily use
Novartis Investigative Site, Vienna
Novartis Investigative Site, Melbourne
Novartis Investigative Site, Melbourne
Novartis Investigative Site, Marseille
Novartis Investigative Site, Córdoba
University of Pennsylvania Clinical, Philadelphia
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Milan
Novartis Investigative Site, Bergamo
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
H Lee Moffitt Cancer Center and Research Institute, Tampa
Novartis Investigative Site, Rennes
Novartis Investigative Site, Salamanca
Sarah Cannon Research Institute, Nashville
Sarah Cannon Research Institute, Nashville
Novartis Investigative Site, Bologna
Novartis Investigative Site, Seville
Novartis Investigative Site, Essen
Novartis Investigative Site, Valencia
Medical College of Wisconsin, Milwaukee
Novartis Investigative Site, Frankfurt am Main
Uni of Chi Medi Ctr Hema and Onco, Chicago
University of Kansas Cancer Center, Westwood
Novartis Investigative Site, Pierre-Bénite
Novartis Investigative Site, Paris
Uni Of TX MD Anderson Cancer Cntr, Houston
St Davids South Austin Medical Ctr, Austin
University of California LA, Los Angeles
Stanford University Medical Center, Stanford
Mass Gen Hosp Cancer Center, Boston
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Badalona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY